According to Zhitong Finance App News, Teda Biotech (08189.HK) announced that for the six months ending June 30, 2026, the Group expects to obtain: revenue of about RMB 290 million to RMB 300 million, an increase of about 28% to 33% over revenue for the six months ending June 30, 2025 (same period last year); and net profit attributable to company owners of about RMB 7 million to RMB 10 million, an increase of about 209% to 256% over the same period last year. Loss becomes profit.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.